{"url_path":"/sec/casif/10-k/2026/item-4a","section_key":"item-4a","section_title":"Item 4A UNRESOLVED STAFF COMMENTS**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1962738/0001104659-26-061632-index.html","accession_number":"0001104659-26-061632","cik":"0001962738","ticker":"CASIF","issuer_name":"CASI Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962738/0001104659-26-061632-index.html","primary_entity_key":"0001962738","primary_entity_name":"CASI Pharmaceuticals, Inc."},"word_count":6,"has_tables":true,"body_markdown":"**ITEM 4A. UNRESOLVED STAFF COMMENTS**\n\nNone."}